Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker: B6E
Tradegate
20.11.26 | 09:54
41,740 Euro
+1,95 % +0,800
Branche
Biotechnologie
Aktienmarkt
Europa 600
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
40,90041,68017:50
40,74041,14020.11.

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSOBI auf der Jefferies Global Healthcare Conference: Markteinführungen als Wachstumstreiber im Fokus3
DiIonis, Sobi granted EU label expansion for Tryngolza3
DiSWEDISH ORPHAN BIOVITRUM AB: Tryngolza (olezarsen) approved in the EU for severe hypertriglyceridaemia (sHTG)2
03.11.Swedish Orphan Biovitrum AB: Sobi to present new gout data at ACR Convergence 2026413Sobi to present new gout data at ACR Convergence 2026 STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced that six abstracts covering pozdeutinurad (AR882), nanoencapsulated...
► Artikel lesen
02.11.Sobi Proposes Former Ericsson CEO Börje Ekholm As New Board Chair10
29.10.Swedish Orphan Biovitrum AB: Börje Ekholm is proposed as new Chair of the Sobi Board of Directors504Börje Ekholm is proposed as new Chair of the Sobi Board of Directors The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi) proposes that Börje Ekholm is elected as new Board member and...
► Artikel lesen
29.10.Swedish Orphan Biovitrum AB: Börje Ekholm is proposed as new Chair of the Sobi Board of Directors135The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi®) proposes that Börje Ekholm is elected as new Board member and Chair of the Board at the 2027 Annual General Meeting (AGM). David Meek...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
29.10.Swedish Orphan Biovitrum AB: Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad428Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad Detailed efficacy and safety results from the pivotal phase 3 study demonstrate...
► Artikel lesen
27.10.Sobi Q3 2026 slides: strong portfolio growth drives guidance upgrade4
27.10.Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 6.96, revenue of SEK 9.12B; updates FY2026 outlook3
27.10.Swedish Orphan Biovitrum Swings To Profit In Q3; Updates FY26 View; Stock Up 2.9%313STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY, BIOVF, SOBI.ST) Tuesday said that it turned to a profit in the third quarter of 2026 from last year's loss, helped by higher revenues...
► Artikel lesen
27.10.Swedish Orphan Biovitrum AB: Sobi Q3 2026 report: Underpinning a strong growth momentum239Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026Third Quarter 2026 • Total revenue increased 16 per cent at CER (constant exchange rates), 17...
► Artikel lesen
19.10.SWEDISH ORPHAN BIOVITRUM AB: Sobi to present new Aspaveli/Empaveli data at ASN Kidney Week 202616
16.10.SWEDISH ORPHAN BIOVITRUM AB: Sobi receives positive CHMP opinion for TRYNGOLZA (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)7
08.10.SWEDISH ORPHAN BIOVITRUM AB: Invitation: Sobi's Q3 2026 report6
01.10.NICE backs Sobi's Tryngolza for rare disease FCS2
01.10.Sobi UK: NICE issues final draft guidance recommending - Tryngolza (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales573FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza (olezarsen)...
► Artikel lesen
24.09.SWEDISH ORPHAN BIOVITRUM AB: Sobi to present clinical data on Gamifant at Histiocyte Society 2026 in Rotterdam8
18.09.Innate Pharma Extends Cash Runway Through Q1 2028 As Sobi Partnership Advances Lacutamab Into Phase 31
16.09.Innate Pharma closes Sobi partnership, receives $75m upfront2
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1